Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations

British Journal of Cancer

Volumn 117, Issue 11, 2017, Pages 1685-1688

  Visco, Carlo ^a,b   Wang, Jinfen ^c   Tisi, Maria Chiara ^a   Deng, Lijuan ^b   D'Amore, Emanuele S G ^a   Tzankov, Alexandar ^d   Montes Moreno, Santiago ^e   Dybkær, Karen ^f   Bhagat, Govind ^g   Hsi, Eric D ^h   Van Krieken, J Han ⁱ   Ponzoni, Maurilio ^j   Ferreri, Andrés J M ^j   Møller, Michael B ^k   Piris, Miguel A ^e   Medeiros, L Jeffrey ^b   Xu Monette, Zijun Y ^b   Young, Ken H ^b,l  

^a SAN BORTOLO HOSPITAL   (Italy)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c SHANXI CANCER HOSPITAL   (China)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^f AALBORG UNIVERSITY HOSPITAL   (Denmark)

^g NewYork Presbyterian Hospital   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^j SAN RAFFAELE HOSPITAL   (Italy)

^k ODENSE UNIVERSITY HOSPITAL   (Denmark)

^l UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

more..

Author keywords

BCL2; diffuse large B cell lymphoma; hepatitis C virus; SIKE 1

Indexed keywords

CYCLIN G2; FAS APOPTOSIS INHIBITORY MOLECULE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LACTATE DEHYDROGENASE; MYC PROTEIN; PROTEIN; PROTEIN BCL 2; PROTEIN BCL 6; PROTEIN P53; TRANSCRIPTION FACTOR C MAF; UNCLASSIFIED DRUG; BCL2 PROTEIN, HUMAN; BCL6 PROTEIN, HUMAN;

ADULT; APOPTOSIS; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DIFFUSE LARGE B CELL LYMPHOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE TRANSLOCATION; HEPATITIS C; HUMAN; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; INTERNATIONAL PROGNOSTIC INDEX; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; PRIORITY JOURNAL; TUMOR IMMUNITY; GENETICS; HEPACIVIRUS; ISOLATION AND PURIFICATION; MIDDLE AGED; ONCOGENE MYC; PATHOLOGY; VIROLOGY;

ADULT; CASE-CONTROL STUDIES; FEMALE; GENES, MYC; HEPACIVIRUS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-BCL-6; TRANSLOCATION, GENETIC;

EID: 85034811846     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2017.345     Document Type: Article

References (15)

1. Arcaini L, Besson C, Frigeni, Fontaine H, Goldaniga M, Casato M, Visentini M, Torres HA, Loustaud-Ratti V, Peveling-Oberhag J, Fabris P, Rossotti R, Zaja F, Rigacci L, Rattotti S, Bruno R, Merli M, Dorival C, Alric L, Jaccard A, Pol S, Carrat F, Ferretti VV, Visco C, Hermine O (2016) Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Blood 128: 2527-2532.
2. Arcaini L, Rossi D, Lucioni M, Nicola M, Bruscaggin A, Fiaccadori V, Riboni R, Ramponi A, Ferretti VV, Cresta S, Casaluci GM, Bonfichi M, Gotti M, Merli M, Maffi A, Arra M, Varettoni M, Rattotti S, Morello L, Guerrera ML, Sciarra R, Gaidano G, Cazzola M, Paulli M (2015) The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection. Haematologica 100: 246-252.
3. Ennishi D, Maeda Y, Niitsu N, Kojima M, Izutsu K, Takizawa J, Kusumoto S, Okamoto M, Yokoyama M, Takamatsu Y, Sunami K, Miyata A, Murayama K, Sakai A, Matsumoto M, Shinagawa K, Takaki A, Matsuo K, Kinoshita T, Tanimoto M (2010) Hepatic toxicity and prognosis in hepatitis C virus infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood 116: 5119-5125.
4. Gloghini A, Dolcetti R, Carbone A (2013) Lymphomas occurring specifically in HIV-infected patients: from pathogenesis to pathology. Semin Cancer Biol 23: 457-467.
5. Mele A, Pulsoni A, Bianco E, Musto P, Szklo A, Sanpaolo MG, Iannitto E, De Renzo A, Martino B, Liso V, Andrizzi C, Pusterla S, Dore F, Maresca M, Rapicetta M, Marcucci F, Mandelli F, Franceschi S (2003) Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood 102: 996-999.
6. Merli M, Visco C, Spina M, Luminari S, Ferretti VV, Gotti M, Rattotti S, Fiaccadori V, Rusconi C, Targhetta C, Stelitano C, Levis A, Ambrosetti A, Rossi D, Rigacci L, D'Arco AM, Musto P, Chiappella A, Baldini L, Bonfichi M, Arcaini L (2014) Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. Haematologica 99: 489-496.
7. Mollejo M, Menárguez J, Guisado-Vasco P, Bento L, Algara P, Montes-Moreno S, Rodriguez-Pinilla MS, Cruz MA, Casado F, Montalbán C, Piris MA (2014) Hepatitis C virus-related lymphoproliferative disorders encompass a broader clinical and morphological spectrum than previously recognized: a clinicopathological study. Mod Pathol 27: 281-293.
8. Peveling-Oberhag J, Arcaini L, Hansmann ML, Zeuzem S (2013) Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol 59: 169-177.
9. Simonin Y, Disson O, Lerat H, Antoine E, Binamé F, Rosenberg AR, Desagher S, Lassus P, Bioulac-Sage P, Hibner U (2009) Calpain activation by hepatitis C virus proteins inhibits the extrinsic apoptotic signaling pathway. Hepatology 50: 1370-1379.
10. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127: 2375-2390.
11. Teramoto T, Satonaka K, Kitazawa S, Fujimori T, Hayashi K, Maeda S (1994) p53 gene abnormalities are closely related to hepatoviral infections and occur at a late stage of hepatocarcinogenesis. Cancer Res 54: 231-235.
12. Tzankov A, Xu-Monette ZY, Gerhard M, Visco C, Dirnhofer S, Gisin N, Dybkaer K, Orazi A, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Ponzoni M, Ferreri AJ, Ye Q, Winter JN, Farnen JP, Piris MA, Møller MB, You MJ, McDonnell T, Medeiros LJ, Young KH (2014) Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol 27: 958-971.
13. Visco C, Finotto S (2014) Hepatitis C virus and diffuse large B-cell lymphoma: pathogenesis, behavior and treatment. World J Gastroenterol 20: 11054-11061.
14. Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Tzankov A, Wen W, Liu WM, Kahl BS, d'Amore ES, Montes-Moreno S, Dybkær K, Chiu A, Tam W, Orazi A, Zu Y, Bhagat G, Winter JN, Wang HY, O'Neill S, Dunphy CH, Hsi ED, Zhao XF, Go RS, Choi WW, Zhou F, Czader M, Tong J, Zhao X, van Krieken JH, Huang Q, Ai W, Etzell J, Ponzoni M, Ferreri AJ, Piris MA, Møller MB, Bueso-Ramos CE, Medeiros LJ, Wu L, Young KH (2012) Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia 26: 2103-2113.
15. Zuckerman E, Zuckerman T, Sahar D, Streichman S, Attias D, Sabo E, Yeshurun D, Rowe J (2001) BCL2 and immunoglobulin gene rearrangement in patients with HCV infection. Br J Haematol 112: 364-369.